The following is a summary of the Theratechnologies Inc. (THTX) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Theratechnologies reported an adjusted EBITDA of $7.2 million and net profit of $3 million for Q3 2024.

• Revenues for Q3 2024 were up 8% year-over-year, primarily driven by strong sales of EGRIFTA SV.

• Adjusted EBITDA guidance for the full year is increased to $17 million to $19 million.

• EGRIFTA SV revenues grew notably by 27% year-over-year to $16.7 million.

• Trogarzo sales stabilized with Q3 revenues at $5.9 million.

Business Progress:

• Strategically focusing on commercializing innovative treatments, the company achieved profitability and adjusted EBITDA positivity.

• Theratechnologies is working on a new formulation, F8 of tesamorelin, expected for resubmission to the FDA by end of November.

• Progress in Phase I clinical trial of sudocetaxel zendusortide for ovarian cancer, with recruitment completed and no DLTs reported.

• Enhancing commercial capabilities and in-licensing discussions signal a strategic push into North American markets.

Opportunities:

• Strong demand and performance of EGRIFTA SV present growth opportunities, despite temporary supply constraints.

• The potential approval and launch of the new tesamorelin formulation (F8) could expand the product portfolio and address unmet medical needs in HIV treatment.

Risks:

• Manufacturing disruptions led to canceled batches of EGRIFTA SV following an FDA inspection, potentially impacting Q4 revenues and total revenue for 2024.

• EGRIFTA SV supply constraints, if prolonged, could affect future revenue streams despite strong market demand.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.